Evotec SE (EVO) Restructuring Costs (2024 - 2025)
Evotec SE's (EVO) quarterly Restructuring Costs came in at -$1629.7 in Q4 2025, down 121.48% year-on-year from $7587.0 in Q4 2024, and down 1390.74% quarter-over-quarter from $126.26 in Q3 2025.
Evotec SE (EVO) Restructuring Costs (2024 - 2025) Analysis & Trends
Evotec SE has disclosed Restructuring Costs across 2 years of filings, most recently posting -$1629.7 for Q4 2025.
- Restructuring Costs for Q4 2025 came in at -$1629.7, down 121.48% year-over-year; the trailing twelve-month figure through Dec 2025 was $12891.5 (changed N/A YoY), and the FY2025 annual result was -$698.43, up 98.81% from the prior year.
- Restructuring Costs came in at -$1629.7 for Q4 2025 at Evotec SE, down from $126.26 in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $7587.0 in Q4 2024 to a low of -$1629.7 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn |
| 10 | Evotec SE | 583.10 Mn | 582.58 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1,629.66 |
| Sep 30, 2025 | 126.26 |
| Dec 31, 2024 | 7,587.03 |
| Sep 30, 2024 | 6,807.86 |